imatinib has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boersma, AW; Brok, M; Burger, H; Nooter, K; Stoter, G; van Tol, H; Wiemer, EA | 1 |
| Bai, F; Chen, Y; Ding, Y; Guo, X; Jiang, S; Kuang, B; Li, CQ; Li, J; Li, L; Liu, J; Liu, Y; Wang, J; Wang, L; Xia, B; Yang, G; Zhang, Q; Zhu, XY | 1 |
2 other study(ies) available for imatinib and imatinib mesylate
| Article | Year |
|---|---|
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Binding, Competitive; Breast Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Mitoxantrone; Mycotoxins; Neoplasm Proteins; Piperazines; Pyrimidines; Substrate Specificity | 2004 |
Total Syntheses and Biological Activities of Vinylamycin Analogues.
Topics: Animals; Anti-Infective Agents; Apoptosis; Bacterial Proteins; Depsipeptides; Heterografts; Humans; K562 Cells; Zebrafish | 2017 |